Zanzalintinib is being tested after Pluvicto (177Lu-PSMA-617) in metastatic castration‑resistant prostate cancer (mCRPC) because it targets several escape routes tumors use once they have survived PSMA‑directed radioligand therapy and prolonged AR pathway blockade. Pluvicto delivers beta radiation to PSMA‑expressing cells, inducing DNA damage and tumor cell death, but progression still occurs and is often driven […]
ABBV-969 is a dual-target antibody-drug conjugate targeting PSMA and STEAP1, data about its radiographic progression-free survival data have just been released, confirming a median rPFS of approximately 15 months in heavily pretreated metastatic castration-resistant prostate cancer. The study demonstrates a signal far exceeding the 4- to 5-month rPFS historically seen with cabazitaxel in the same […]
CD46 is a cell‑surface protein that stays highly expressed in aggressive, late‑stage prostate cancer, including PSMA‑low, AR‑negative and neuroendocrine variants. That means CD46 immunoPET can still “see” and quantify disease that PSMA PET misses, and can guide CD46‑targeted therapies in exactly those PSMA‑low/negative patients who respond poorly to PSMA‑directed radioligand therapy. Using the human antibody […]
The PROTEUS phase 3 trial, published in the New England Journal of Medicine, shows that adding perioperative apalutamide to androgen-deprivation therapy significantly improves outcomes for men with high-risk localized or locally advanced prostate cancer undergoing radical prostatectomy. The international trial randomized 2,109 patients to six cycles of ADT plus apalutamide (240 mg daily) or ADT […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! From the hottest Italian May I can remember, here’s what’s happening in cancer research and clinical trials. Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find […]
A pivotal Phase 3 trial called VECTRA-01 has launched to evaluate AZD2265 (²²⁵Ac-PSMA-I&T), an alpha-emitting radioligand therapy targeting PSMA-positive metastatic castration-resistant prostate cancer. The study began in May 2026, enrolling approximately 670 participants across 90 global sites, with recruitment currently active at select locations. The trial’s primary objective is to demonstrate superiority over standard of […]
Zanzalintinib is a new investigational drug showing activity in metastatic castrate-resistant prostate cancer (mCRPC), particularly in patients with soft tissue or visceral metastases who have progressed on prior treatment. A single-arm Phase II trial is evaluating whether zanzalintinib is effective for this difficult-to-treat population. Participants can stay in the study for up to 24 months […]
Mevrometostat is an oral EZH2 inhibitor being developed to overcome resistance to androgen‑receptor–targeted therapy in prostate cancer. In tumors, EZH2 helps switch off tumor‑suppressor genes and supports androgen‑independent growth and lineage plasticity, changes that are strongly linked to progression on drugs like enzalutamide. Adding an EZH2 inhibitor to continued AR blockade is meant to “re‑discipline” […]
In the phase 3 CaBRA trial, carboplatin is added to the docetaxel-based chemotherapy backbone used with lifelong ADT (androgen deprivation therapy) and darolutamide, creating a quadruple-intensification therapy for a small but very high-risk subgroup of metastatic castration-sensitive prostate cancer. The trial focuses on tumors with either BRCA alterations or neuroendocrine differentiation, two features that are […]
Researchers have identified SIRT1 as a promising new target in neuroendocrine prostate cancer, a rare but highly aggressive subtype that often develops after standard hormone therapy stops working. The finding is important because this form of prostate cancer is especially hard to treat and tends to behave more aggressively than typical androgen-driven disease. The study […]